Influenza A virus subtype H1N1

Europe Air Purifiers Market Report 2023: New Air Purifier Launches Take the European Market by Storm - Forecasts to 2028 - ResearchAndMarkets.com

Retrieved on: 
Friday, August 4, 2023
Retail, Other Retail, Pressure, Electron, Allergy, Ultra-low particulate air, COPI, Atmosphere, Internet of things, Gas, NO2, Stroke, Coronavirus, Influenza A virus subtype H1N1, Lung cancer, Pollen, Molekule, Public interest, Science, Pollutant, Chronic obstructive pulmonary disease, HVAC, Market, Nitrogen dioxide, Streamer, Risk, AHU, Smoke, PM10, Particulates, Bluetooth, United Kingdom, City, HEPA, Filtration, Bacteria, PECO, MITES, Health, Growth, WHO, Air pollution, Allergen, Virus, Imperial College London, Pneumonia, Environment, World Health Organization, Vaccine, Environmental remediation, Daikin, H1N1

In the industrial setting, air purifiers can be utilized to clean the air before processing.

Key Points: 
  • In the industrial setting, air purifiers can be utilized to clean the air before processing.
  • Technology-based air purifiers are further influencing the growth of the air purifiers market in Europe.
  • Therefore, rising air pollution drives the market for air purifiers in Europe.
  • Company Profiles: Detailed analysis of the major companies present in Europe air purifiers market.

Integrated DNA Technologies Launches New Respiratory Virus Panel

Retrieved on: 
Wednesday, July 19, 2023
Technology, Manufacturing, Health, General Health, Health Technology, Other Technology, Research, Other Manufacturing, Infectious Diseases, Genetics, Science, Influenza A virus subtype H1N1, XGen Studios, Respiratory tract infection, Therapy, SARS-CoV-2, Infection, NGS, Integrated DNA Technologies, COVID-19, Season, Multimedia, Doctor of Philosophy, IDT, RSV, R, Integration, Virus, A-DNA, Vaccine

To meet customer demand for a multiplexed, multiple respiratory disease target panel that provides comprehensive genome coverage, Integrated DNA Technologies (IDT) is revealing a new next generation sequencing (NGS) solution, the xGen Respiratory Virus Amplicon Panel .

Key Points: 
  • To meet customer demand for a multiplexed, multiple respiratory disease target panel that provides comprehensive genome coverage, Integrated DNA Technologies (IDT) is revealing a new next generation sequencing (NGS) solution, the xGen Respiratory Virus Amplicon Panel .
  • Leveraging IDT’s well-established NGS amplicon technology, the panel creates super amplicons to reliably distinguish identified and unidentified viral variants of multiple respiratory viruses in a single panel and allows for tracing evolving epidemiological patterns.
  • View the full release here: https://www.businesswire.com/news/home/20230719949441/en/
    Integrated DNA Technologies is revealing a new next generation sequencing (NGS) solution, the xGen™ Respiratory Virus Amplicon Panel, to support researchers as they combat the challenging diseases of today and prepare for the next pathogen of tomorrow.
  • The xGen Respiratory Virus Amplicon Panel is also compatible with IDT Normalase™ technology .

Test Results Indicate that Molekule’s Air Pro Purifier Reduces Hospital Length of Stay by Approximately Two Days in COVID-19 Patients

Retrieved on: 
Tuesday, June 27, 2023
PALM, PM-2.5, University, Atmosphere, SARS-CoV-2, COVID-19, Influenza A virus subtype H1N1, IAQ, University of South Florida, Volatile organic compound, Temperature, CO, Humidity, Mercyhealth, BEACH, Patient, Length of stay, Randomized controlled trial, Ozone, Bacteria, PECO, Health, FDA, Virus, Allergen, CO2, Hospital, Molekule

PALM BEACH GARDENS, Fla., June 27, 2023 (GLOBE NEWSWIRE) --  Molekule Group, Inc. (“Molekule” or the “Company”) (Nasdaq: MKUL) today announced the results of a research study evaluating the effect of in-room air purification on the clinical recovery in mild and moderate COVID-19 patients. The study, conducted at two Mercyhealth hospitals, indicates a statistically significant outcome, with length of stay reduced by approximately two (2) days when Molekule’s Air Pro purifier with its patented PECO filter is running in the patient room.

Key Points: 
  • The study, conducted at two Mercyhealth hospitals, indicates a statistically significant outcome, with length of stay reduced by approximately two (2) days when Molekule’s Air Pro purifier with its patented PECO filter is running in the patient room.
  • “We know our devices are proven to effectively destroy many dangerous pathogens from the air.
  • “The results from the adequately powered blinded randomized controlled trial comparing Molekule’s Air Pro purifier versus placebo shows that, on average, use of Molekule’s Air Pro purifier was associated with a two day shorter stay in the hospital for COVID-19 patients - the primary outcome of the trial.
  • On average, patients with Air Pro devices with filter use stayed two days less in the hospital compared with placebo devices.

Molekule Signs Agreement to Provide Air Quality Monitoring Services to Veterans Affairs Facilities

Retrieved on: 
Thursday, May 4, 2023
PALM, VHA, Atmosphere, SARS-CoV-2, Organic compound, Influenza A virus subtype H1N1, IAQ, Woman, Volatile organic compound, Intelligence, Temperature, Veteran, POV, HVAC, Humidity, RSV, Visn, Veterans' affairs, Particulates, Health, FDA, Air quality index, Allergen, CO2, Safety, Real estate, Molekule

The mobilized solution allows the VA administration to access real-time IAQ data and receive alerts when IAQ levels exceed predetermined thresholds.

Key Points: 
  • The mobilized solution allows the VA administration to access real-time IAQ data and receive alerts when IAQ levels exceed predetermined thresholds.
  • The system gives VISN 23 operators recommendations for maintaining optimal air quality and evidence of the current state of IAQ.
  • Molekule implemented advanced IAQ monitoring technology and services in three VA service centers in Hot Springs, SD, Ft. Riley, KS, and Topeka, KS, and the solution has been running successfully for over a year.
  • The devices are part of a state-of-the-art advanced solutions platform, which includes IAQ monitoring and internet-of-things (“IoT”) device control.

Molekule and Aura Expand in Global Education Market with Multiple Deployments and Orders

Retrieved on: 
Friday, April 28, 2023
PALM, Ohio University, University, Education, SARS-CoV-2, Internet of things, Performing arts education in Australia, Influenza A virus subtype H1N1, IAQ, Volatile organic compound, University of Pennsylvania, Indoor air quality, EPA, School, Influenza, Student, RSV, Acquisition, Smoke, Northeastern University, Bacteria, FDA, Air pollution, Allergen, Software, Medical device, Molekule

Molekule and Aura technologies include the largest range of proprietary and patented, FDA-cleared air purification devices, which have been proven to destroy SARS-CoV-2, RSV, H1N1 flu virus, VOCs, allergens, mold and many other pollutants.

Key Points: 
  • Molekule and Aura technologies include the largest range of proprietary and patented, FDA-cleared air purification devices, which have been proven to destroy SARS-CoV-2, RSV, H1N1 flu virus, VOCs, allergens, mold and many other pollutants.
  • Globally, Aura is also expanding across several schools and districts in Israel and Hong Kong.
  • Jason DiBona, Chief Executive Officer of Molekule, noted, “Both Molekule and Aura provide an instantly deployable air quality and purification solution for the education sector, which includes software to enable users to assess and mitigate air quality across numerous devices.
  • Aura’s software capabilities enable centralized monitoring and remote management of installed units to ensure indoor air safety and quality.

Launching an Innovative Product, PlaClin-M, for Safe Environments in the Pandemic Era.

Retrieved on: 
Thursday, March 23, 2023
CE, Human, Travel, Carnival, Vaccination, Airport, Ebola, Ambulance, Infection, Influenza A virus subtype H1N1, Government, Sterilization, Intensive care medicine, Korean Air, Ministry, COVID-19, Operating, ICT, MD, Tuberculosis, Mers, Disinfectant, Royal Caribbean, Mortality, FDA, Environment, Amazon, Ministry of Science and ICT, Pharmaceutical industry, Science, Japan Airlines

CodeSteri started from the Korean government project to combat new infectious diseases by the incumbent professor and MD of Hanyang University Emergency Medicine, Seoul.

Key Points: 
  • CodeSteri started from the Korean government project to combat new infectious diseases by the incumbent professor and MD of Hanyang University Emergency Medicine, Seoul.
  • PlaClin was awarded as an "Innovative Product" by the Ministry of Science and ICT and patented in USA and Korea.
  • Such airlines as Korean Airlines, Japan Airlines, and other major airlines can benefit a lot from using innovative PlaClin solutions.
  • They can offer more safe travel environments to their customers and cost saving to themselves.

Launching an Innovative Product, PlaClin-M, for Safe Environments in the Pandemic Era.

Retrieved on: 
Thursday, March 23, 2023
CE, Human, Travel, Carnival, Vaccination, Airport, Ebola, Ambulance, Infection, Influenza A virus subtype H1N1, Government, Sterilization, Intensive care medicine, Korean Air, Ministry, COVID-19, Operating, ICT, MD, Tuberculosis, Mers, Disinfectant, Royal Caribbean, Mortality, FDA, Environment, Amazon, Ministry of Science and ICT, Pharmaceutical industry, Science, Japan Airlines

CodeSteri started from the Korean government project to combat new infectious diseases by the incumbent professor and MD of Hanyang University Emergency Medicine, Seoul.

Key Points: 
  • CodeSteri started from the Korean government project to combat new infectious diseases by the incumbent professor and MD of Hanyang University Emergency Medicine, Seoul.
  • PlaClin was awarded as an "Innovative Product" by the Ministry of Science and ICT and patented in USA and Korea.
  • Such airlines as Korean Airlines, Japan Airlines, and other major airlines can benefit a lot from using innovative PlaClin solutions.
  • They can offer more safe travel environments to their customers and cost saving to themselves.

SINOVAC Varicella Vaccine Prequalified by WHO

Retrieved on: 
Friday, November 4, 2022
Health, Infectious Diseases, COVID-19, Clinical Trials, Pharmaceutical, Biotechnology, Company, Mumps, Polio, III, World, Influenza A virus subtype H1N1, World Health Organization, WHO, Foot-and-mouth disease virus, Hepatitis A, Vaccine, COVID-19, H5N1, CEO, National TB Elimination Program (India), Chickenpox, Seroconversion, HFMD, Oka, NASDAQ, Infection, R, Streptococcus, EV71, Program, Sinovac Biotech

This marks the first WHO prequalified Chinese varicella vaccine and the fourth SINOVAC vaccine to receive WHO approval.

Key Points: 
  • This marks the first WHO prequalified Chinese varicella vaccine and the fourth SINOVAC vaccine to receive WHO approval.
  • Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented, Now that SINOVAC has received WHO prequalification for our varicella vaccine, we can provide a new weapon for prevention and control of infectious diseases globally.
  • Previously, three other vaccines by SINOVAC were also approved by WHO in various uses and conditions, including Healive (the hepatitis A vaccine), CoronaVac (the COVID-19 vaccine) and the Sabin-strain inactivated polio vaccine.
  • In 2022, SINOVACs Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.

Global Antimicrobial Coatings Market Report 2022: High Demand for Antimicrobial Coatings in the Medical & Healthcare Sector Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 2, 2022
Chemicals, Plastics, Manufacturing, Eyeish, Awareness, Influenza A virus subtype H1N1, Growth, Region, Transport, Health, Nanoparticle, COVID, Aladdin (food & beverage containers), HVAC, Ion, Virus, COVID-19, Bacteria, Medicine, Personal protective equipment, Silver, CAGR, Department of Building Construction Management Technology, Purdue University, Health care, Adoption, USD, COVID 19, Subclinical infection, Bed, Copper, Listeria, Titanium, Copper

Out of three (Silver, Copper and Titanium dioxide) Silver is the major type of antimicrobial coatings.

Key Points: 
  • Out of three (Silver, Copper and Titanium dioxide) Silver is the major type of antimicrobial coatings.
  • In the medical & healthcare sector, the growing concern about hospital-acquired infections (HAIs) and their related impact on human health is driving the adoption of antimicrobial coatings.
  • Antimicrobial coatings have thus emerged as an effective solution in the medical & healthcare sector to fight COVID-19.
  • However, due to COVID-19, there has been a significant increase in the demand for antimicrobial coatings in medical & healthcare, protective coating, and HVAC system applications.

SINOVAC to Showcase Products at CPHI Frankfurt

Retrieved on: 
Friday, October 28, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious Diseases, R, Chickenpox, Company, Influenza A virus subtype H1N1, Mumps, NASDAQ, Polio, H5N1, Vaccine, Pyaar Tune Kya Kiya (TV series), Foot-and-mouth disease virus, Booth, EV71, Streptococcus, Program, COVID-19, Infection, HFMD, Hepatitis A, WHO, Sinovac Biotech, Fine chemical

Sinovac Biotech Ltd. (SINOVAC or the Company) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Company will participate in CPHI Frankfurt, one of the worlds largest pharmaceutical exhibitions, from 1st to 3rd of November, in Frankfurt, Germany.

Key Points: 
  • Sinovac Biotech Ltd. (SINOVAC or the Company) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Company will participate in CPHI Frankfurt, one of the worlds largest pharmaceutical exhibitions, from 1st to 3rd of November, in Frankfurt, Germany.
  • At Booth#41G20, the first floor of Hall 4, Messe Frankfurt, SINOVAC will greet all visitors of CPHI and present its comprehensive portfolio.
  • Helen Yang, Chief Business Officer of SINOVAC said, SINOVAC is an old friend of CPHI, and we are happy to finally return to CPHIs in-person event for the first time since the outbreak of the COVID-19 pandemic globally.
  • SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities.